Copyright
©The Author(s) 2022.
World J Cardiol. Jan 26, 2022; 14(1): 29-39
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.29
Published online Jan 26, 2022. doi: 10.4330/wjc.v14.i1.29
Inherited CMP | Prevalence | Pattern of inheritance | Key genes | Diagnostic yield of genetic testing | Recommendation for genetic testing |
HCM | 1 in 500 | AD | MYH7, MYBPC3, TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3, GLA, PRKAG2, LAMP2 | 30%-60% | For any patient with clinical diagnosis of HCM; Familial screening with a mutation after identified in the index case |
DCM | 1 in 2500 | AD, X-linked | DES, DMD, DSP, FLNC, LMNA, MYH7, PLN, RBM20, TNNI3, TNNT2, TTN, TPM1 | 20%-30% | For patients with DCM and conduction disease and/or family history of SCD; Familial screening with a mutation after identified in the index case |
ARVC | 1 in 2000-5000 | AD, AR | DSC2, DSG2, DSP, JUP, PLN, TMEM43 | 50% | Familial screening with a mutation after identified in the index case |
RCM | Rare | AD, AR X-linked or mitochondrial | Troponin; MYBPC3, MYL3 | Unknown | Familial screening with a mutation after identified in the index case |
- Citation: Vogiatzi G, Lazaros G, Oikonomou E, Lazarou E, Vavuranakis E, Tousoulis D. Role of genetic testing in cardiomyopathies: Α primer for cardiologists. World J Cardiol 2022; 14(1): 29-39
- URL: https://www.wjgnet.com/1949-8462/full/v14/i1/29.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i1.29